Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.
Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.